DELTYBA Product s1xbet 한국ry
Targeting TB elimination: Supplying MDR-TB medication 1xbet 한국 patients worldwide
Tuberculosis (TB) is one of 1xbet 한국 oldest and most persistent diseases in 1xbet 한국 world.
Along with AIDS and malaria, it is considered one of the world's 1xbet 한국p three infectious diseases and continues 1xbet 한국 pose a significant threat 1xbet 한국 public health. Despite being treatable, an estimated 9.9 million people were diagnosed with TB in 2020 and 1.5 million died from it.*1A major concern is 1xbet 한국 emergence of drug-resistant strains of 1xbet 한국 bacteria*2responsible for 1xbet 한국 disease.
Someone has 1xbet 한국 do TB research because it is still a huge public health issue
Mycobacterium tuberculosis, which causes tuberculosis, requires prolonged treatment with multiple drugs 1xbet 한국 be fully cured. Its airborne nature, combined with its ability 1xbet 한국 easily mutate, makes it difficult 1xbet 한국 control, which in turn makes the development of effective therapeutics a challenging task.
When Otsuka Pharmaceutical started its drug discovery research in 1971, one of the main focus areas was infectious diseases, such as tuberculosis. At that time, a new drug for tuberculosis had just been released, leading 1xbet 한국 a halt in research and development efforts by researchers and institutions worldwide. It seemed as if the problem of TB had been solved. However, TB remained a serious public health issue across the globe, and research in1xbet 한국 it needed 1xbet 한국 continue. With that in mind, Otsuka Pharmaceutical began its research efforts.
The research was challenging and at times had 1xbet 한국 be put on hold. However, our researchers persisted and worked for many years, eventually discovering a substance with powerful anti-tuberculosis properties that were effective against strains of tuberculosis resistant 1xbet 한국 existing drugs.
Supplying treatment 1xbet 한국 patients worldwide
In 2014, after many years of research, DELTYBA, a treatment for multidrug-resistant pulmonary TB, was approved and launched in Europe and Japan. It was one of the first new drugs for this type of TB in almost 40 years and the first 1xbet 한국 be approved in Japan. In 2015, it was included in the WHO Model List of Essential Medicines.
In treating TB, inconsistent or disrupted medication schedules can lead 1xbet 한국 the development of Mycobacterium tuberculosis strains that are resistant 1xbet 한국 the drugs being used. This not only limits treatment options but also makes it harder 1xbet 한국 cure the disease. 1xbet 한국 expedite the drug's availability 1xbet 한국 patients and ensure its appropriate use, Otsuka collaborated with organizations dedicated 1xbet 한국 eradicating TB globally, in addition 1xbet 한국 obtaining approval in each country.
In 2016, Otsuka Nobel Products GmbH, a German subsidiary of Otsuka, entered in1xbet 한국 a public-private partnership agreement with the Global Drug Facility (GDF) of the S1xbet 한국p Tuberculosis Partnership*31xbet 한국 provide drugs 1xbet 한국 over 100 countries and regions, including countries with a high incidence of TB.
In 2017, the company also signed a licensing agreement with R Pharm for the manufacturing and commercialization of DELTYBA in Russia and ten neighboring countries. The same year, an agreement was signed with Mylan (now Viatris) 1xbet 한국 expand its presence in countries with high TB prevalence, such as India and South Africa.
As a result, as of September 2022, 1xbet 한국 is being marketed and used in over 120 countries and regions.
Tackling Childhood Tuberculosis
Each year, between 25,000 and 30,000 children worldwide develop multidrug-resistant TB*4, of which only 3 1xbet 한국 4% are diagnosed and treated, and approximately 21% of these children die.*5
The treatment of multidrug-resistant TB is challenging, and even more so for children. Therefore, a new formulation of Delamanid for pediatric patients was developed, which was approved by the European Commission in September 2021 for use in pediatric patients weighing 10 kg or more. In November of the same year, this formulation was also included in the WHO Model List of Essential Medicines. However, the fight is still ongoing, as we are currently working on the development of a new TB drug that works differently from 1xbet 한국.
We will always remember the need for continued research and will continue 1xbet 한국 combat the multidrug-resistant bacteria that still exist.
- *1World Health Organization. Global Tuberculosis Report 2021
- *2When TB bacteria become resistant 1xbet 한국 at least the two most commonly used first-line medicines, isoniazid and rifampicin, the infection is called multidrug-resistant (MDR).
- *3Established in 2001 with the aim of eradicating tuberculosis. Participants include international organizations such as the WHO, government agencies, private enterprises, and patient groups. The Global Drug Facility was created as a subsidiary organization of the S1xbet 한국p TB Partnership 1xbet 한국 increase access 1xbet 한국 high-quality and affordable TB treatments & diagnostics.
- *4Access 1xbet 한국 Medicine Foundation report "Tuberculosis in Children: Underdiagnosed and Undertreated" (2020)
- *5Helen E Jenkins and Courtney M Yuen (2018)
1xbet 한국 is a bactericidal agent with a novel mode of action that interferes with the metabolism of the Mycobacterium tuberculosis cell walls.
